Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Aug;40(8):2561-2569.
doi: 10.1007/s00467-025-06769-3. Epub 2025 Apr 11.

Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis

Yanyan Jin  1 , Jianhong Zhu  2 , Aiqin Sheng  1 , Qian Lin  1 , Manli Zhao  3 , Xue He  1 , Jianhua Mao  1 , Haidong Fu  4
Affiliations
Observational Study

Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis

Yanyan Jin et al. Pediatr Nephrol. 2025 Aug.

Abstract

Background: Persistent proteinuria is an independent risk factor for poor prognosis in immunoglobulin A vasculitis nephritis (IgAVN). Recent studies have shown that telitacicept effectively reduces proteinuria levels in patients with IgA nephropathy (IgAN). The treatment has been associated with a significant decrease in galactose-deficient IgA1 (Gd-IgA1) levels. This study aims to elucidate the effectiveness and safety of telitacicept in treating refractory childhood IgAVN.

Methods: This is a single-center, retrospective observational study of seven children with IgAVN who had previously received glucocorticoids and at least one immunosuppressive therapy but still exhibited proteinuria. Telitacicept was administered subcutaneously once a week. Dosage was 80 mg for individuals weighing < 40 kg and 160 mg for those weighing > 40 kg.

Results: The study encompassed seven children, comprising two boys and five girls, with a median age of 15 years. Among the participants, six children (85.7%) exhibited a reduction in proteinuria, ranging from - 23.6 to - 97.5% compared to baseline levels. Conversely, one child (14.3%) did not show any decrease in proteinuria. Throughout the follow-up period, two children (28.6%) achieved complete remission, characterized by proteinuria level below 0.2 g/day/1.73 m2 and negative dipstick test for blood. Additionally, all participants demonstrated a significant decline in urinary red blood cell counts. In terms of medication administration, all patients discontinued the use of steroids and immunosuppressants. Furthermore, there was a reduction in the incidence of hospitalizations. Importantly, no serious adverse reactions were reported.

Conclusions: Telitacicept has demonstrated both efficacy and safety in treating children with refractory IgAVN.

Keywords: BAFF/APRIL inhibitors; Children; IgA vasculitis nephritis; Proteinuria; Refractory; Telitacicept.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study has been ethically reviewed and approved by the Ethics Committee of Children’s Hospital, Zhejiang University School of Medicine, as indicated by the approval number (2024-IRB- 0263-P- 01). In line with ethical standards, informed consent has been secured from the guardians of the participating children. Competing interests: The authors declare no competing interests.

References

    1. Watts RA, Hatemi G, Burns JC, Mohammad AJ (2022) Global epidemiology of vasculitis. Nat Rev Rheumatol 18:22–34. https://doi.org/10.1038/s41584-021-00718-8 - DOI - PubMed
    1. Jin Y, He X, Lin W, Peng Z, Li W, Xiang W, Chen Z, Fu H, Mao J (2014) Serum cytokine profiles in children with IgA vasculitis with nephritis. Biomol Biomed. https://doi.org/10.17305/bb.2024.11081
    1. Sugino H, Sawada Y, Nakamura M (2021) IgA vasculitis: etiology, treatment, biomarkers and epigenetic changes. Int J Mol Sci 22:7538. https://doi.org/10.3390/ijms22147538 - DOI - PubMed - PMC
    1. Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet 360:666–670. https://doi.org/10.1016/S0140-6736(02)09835-5 - DOI - PubMed
    1. Coppo R, Andrulli S, Amore A, Gianoglio B et al (2006) Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis 47:993–1003. https://doi.org/10.1053/j.ajkd.2006.02.178 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources